Click image to enlarge
The
U-PLEX platform offers validated components that can be combined to create high quality assays quickly and easily. The U-PLEX Human vWF 384-well Assay has the essential components for an assay that measures vWF in a single-analyte format on 384-well plates. For information on multiplexing vWF with other analytes, please see
U-PLEX Custom Biomarker Group 3 (human) Assays.
Related Key Terms:
von Willebrand factor, VWD, F8VWF, hemostasis, thrombosis
-
-
Specifications
-
Kit Contents
-
Documentation
-
References
Application(s)
|
|
Oncology & Cancer
,
Cardiovascular
|
|
Analyte(s)
|
|
vWF
|
|
Species
|
|
Human
|
|
Instrument(s)
|
|
MESO SECTOR S 600
,
SECTOR Imager 6000
,
MESO SECTOR S 600MM
|
|
U-PLEX Group Compatibility
|
|
Biomarker Group 3
|
|
Plate Type
|
|
384-well
|
|
Capture Antibody
|
|
Mouse Monoclonal
|
|
Detection Antibody
|
|
Mouse Monoclonal
|
|
LLOD (Sensitivity)
|
|
67.4 pg/mL
|
|
Dynamic Range
|
|
67.4 - 1,000,000 pg/mL
|
|
Sample Type
|
|
Cell Culture Media, Plasma, Serum
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
Storage Statement(s)
|
|
Please refer to the product insert for the storage conditions of individual kit components.
|
|
Storage Condition
|
|
Multi-Component
|
|
Gene ID(s)
|
|
7450
|
|
UniProt ID(s)
|
|
P04275
|
|
Schedule B Code
|
|
3822.19.0000
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
2-8 °C
|
1 each (5 plate size)
|
|
|
2-8 °C
|
5 vial (1 vial)
|
|
|
2-8 °C
|
5 each (1 plate)
|
|
|
2-8 °C
|
1 bottle (1000 mL)
|
|
|
≤-10 °C
|
3 bottle (200 mL)
|
|
|
≤-10 °C
|
2 bottle (50 mL)
|
|
|
RT
|
1 bottle (90 mL)
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
2-8 °C
|
5 each (5 plate size)
|
|
|
2-8 °C
|
25 vial (1 vial)
|
|
|
2-8 °C
|
25 each (1 plate)
|
|
|
2-8 °C
|
5 bottle (1000 mL)
|
|
|
≤-10 °C
|
12 bottle (200 mL)
|
|
|
≤-10 °C
|
10 bottle (50 mL)
|
|
|
RT
|
5 bottle (90 mL)
|
|
Product Inserts
|
|
|
Datasheets
|
|
|
Product Highlights
|
|
|
SDS
|
|
|
Title
|
Journal
|
Year
|
|
Kinetics and Biomarkers of Severe Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor-modified T Cell Therapy.
|
|
|
|
|
Order Details
Catalog No
Size
Price in USD
Qty
Customer Service/Orders
Scientific/Technical Support
Instrument Support
Company Headquarters